Trial Outcomes & Findings for Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea (NCT NCT03109418)

NCT ID: NCT03109418

Last Updated: 2019-12-19

Results Overview

Visual Analog Scale pain rating

Recruitment status

TERMINATED

Study phase

PHASE2/PHASE3

Target enrollment

9 participants

Primary outcome timeframe

up to 24 hours postoperatively

Results posted on

2019-12-19

Participant Flow

Three participants were excluded prior to randomization due to the following reasons: 1. The patient was experiencing on-going neurological issues and was therefore removed from the study prior to randomization. 2. The patient missed his/her own surgery date. 3. The patient ended up having outpatient surgery, and was therefore excluded.

Participant milestones

Participant milestones
Measure
Control Group
OSA patients will receive standard inhaled anesthesia with normal saline infusion Control: OSA patients receiving standard inhaled anesthesia combined with normal saline
Ketamine Group
OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion. Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
Overall Study
STARTED
2
4
Overall Study
COMPLETED
2
3
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control Group
n=2 Participants
OSA patients will receive standard inhaled anesthesia with normal saline infusion Control: OSA patients receiving standard inhaled anesthesia combined with normal saline
Ketamine Group
n=3 Participants
OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion. Ketamine: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
Total
n=5 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Sex/Gender, Customized
Males
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Sex/Gender, Customized
Female
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race/Ethnicity, Customized
Caucasian
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Race/Ethnicity, Customized
African-American
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic/Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Other
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: up to 24 hours postoperatively

Population: Study was terminated. Data was not collected.

Visual Analog Scale pain rating

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At 24 hrs post-op

Population: Participants were not analyzed due to study being terminated. Data was not collected.

Patients will rate their quality of anesthesia services

Outcome measures

Outcome data not reported

Adverse Events

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Ketamine Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Adam Sturdivant

University of Alabama at Birmingham

Phone: 205-934-4042

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place